Get the Stockscreener App
0.6098
2.24%
-0.0142
Oragenics Inc stock is traded at $0.6098, with a volume of 15,168.
It is down -2.24% in the last 24 hours and down -30.67% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.624
Open:
$0.633
24h Volume:
15,168
Relative Volume:
0.03
Market Cap:
$2.67M
Revenue:
$7,500
Net Income/Loss:
$-9.84M
P/E Ratio:
-0.1065
EPS:
-5.7263
Net Cash Flow:
$-9.25M
1W Performance:
-18.90%
1M Performance:
-30.67%
6M Performance:
-51.97%
1Y Performance:
-91.74%
1-Day Range:
$0.61
$0.6399
1-Week Range:
$0.61
$0.746
52-Week Range:
$0.61
$9.60
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.6154 | 2.71M | 7,500 | -9.84M | -9.25M | -5.7263 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Oragenics Inc Stock (OGEN) Latest News
Oragenics (OGEN) Reports Going Concern Risk in Latest Audit - GuruFocus
OGEN SEC FilingsOragenics 10-K, 10-Q, 8-K Forms - Stock Titan
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - GlobeNewswire
Volume Recap: Is Oragenics Inc vulnerable to short sellers2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
If You Invested $1,000 in Oragenics (OGEN) - Stock Titan
[EFFECT] ORAGENICS INC SEC Filing - Stock Titan
Growth Report: Is Oragenics Inc forming bullish engulfing patterns2026 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
OGEN Forecast, Price Target & Analyst Ratings | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics (NASDAQ: OGEN) updates S-3/A with auditor consent - Stock Titan
Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development - citybuzz -
Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates - geneonline.com
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K - The Manila Times
Biotech Oragenics raises $16.5M, clears debt to fund concussion drug trial - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oragenics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - Sahm
Oragenics Initiates First Clinical Site for Phase IIa Trial of Intranasal Concussion Treatment - citybuzz -
Oragenics Inc Initiates Phase Iia Clinical Trial Site Activation - marketscreener.com
Oragenics (OGEN) Advances Phase IIa Clinical Trial of ONP-002 in Australia - GuruFocus
Oragenics begins testing nasal concussion treatment in Australia - Stock Titan
Oragenics Receives Australian HREC Approval to Begin Phase IIa Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury - Minichart
Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions - TipRanks
Oragenics Explores CNS Asset Acquisitions to Expand Brain Health Pipeline - citybuzz -
Oragenics (OGEN) Eyes Expansion in Central Nervous System Sector - GuruFocus
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - The Manila Times
Oragenics (OGEN) Receives Approval for Phase IIa Concussion Drug Trial in Australia - GuruFocus
Oragenics Receives HREC Approval for Phase IIa Clinical - GlobeNewswire
Is Oragenics Inc forming bullish engulfing patterns2025 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Inflation Data: Is Oragenics Inc a strong candidate for buy and holdJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
Aug Technicals: What is the target price for Oragenics Inc stockPortfolio Performance Report & Momentum Based Trading Signals - baoquankhu1.vn
OGEN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Momentum Shift: Is Oragenics Inc vulnerable to short sellersJuly 2025 Update & Weekly Breakout Stock Alerts - baoquankhu1.vn
How Oragenics Inc. stock trades pre earningsJuly 2025 Pullbacks & Risk Managed Investment Entry Signals - mfd.ru
OGEN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can Oragenics Inc. sustain its profitabilityJuly 2025 Macro Moves & Consistent Return Investment Signals - mfd.ru
Is Oragenics Inc. vulnerable to short sellers2025 Key Lessons & Verified Chart Pattern Signals - mfd.ru
Oragenics previews targeted milestones for 2026 - Yahoo Finance
Oragenics (OGEN) Progresses ONP-002 for Potential $9 Billion Con - GuruFocus
Oragenics Targets Projected $9 Billion Market by Advancing - GlobeNewswire
Portfolio Shifts: What is the next catalyst for Oragenics IncJuly 2025 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Oragenics partners with Duck Flats Pharma to support FDA IND trial design - Yahoo Finance
Oragenics (OGEN) Partners with Duck Flats Pharma for U.S. IND Re - GuruFocus
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program - Sahm
Oragenics Advances Concussion Treatment Development with SCOPE Summit Participation Ahead of Australian Phase 2a Trial - citybuzz -
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care - GlobeNewswire
Investor Mood: Is Oragenics Inc stock technically oversold2025 Risk Factors & Growth Focused Stock Reports - baoquankhu1.vn
Market Trends: Is now the right time to enter LPLAWeekly Trade Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Rate Hike: What is the next catalyst for Oragenics IncQuarterly Portfolio Summary & Verified Entry Point Detection - baoquankhu1.vn
Oragenics Extends At-the-Market Equity Sales Agreement - The Globe and Mail
Oragenics amends at-the-market sales agreement with Dawson James Securities By Investing.com - Investing.com Australia
Oragenics amends at-the-market sales agreement with Dawson James Securities - Investing.com
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):